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Abstract
Background: It is designed to investigate the effects of combination therapy of allicin and fenofibrate on the
endothelial and liver functions in rats with hyperlipidemia.
Methods: The healthy male Wistar rats fed high fat diet were treated with fenofibrate (80 mg/kg per day) alone,
allicin (60 mg/kg per day) alone and a lower dasage of combined therapy (allicin 20 mg/kg per day and
fenofibrate 30 mg/kg per day) respectively for 8 weeks. The serum levels of cholesterol, triglyceride, nitrogen
oxidative, alanine transferase (ALT) and aspartate transferase (AST) were determined. Acetylcholine-induced
endothelium-dependent vascular relaxation (EDVR) of aorta rings was tested, and the morphologic changes of liver
tissue were observed.
Results: Compared with high fat diet control, fenofibrate alone or the combined therapy increased remarkably the
levels of high density lipoprotein respectively (P < 0.05). Both single and combined therapy of fenofibrate and
allicin significantly enhanced the levels of NO (P < 0.01 or P < 0.05), but the combined therapy had greatest high
EDVR responses (P < 0.01). Furthermore, the reduced levels of ALT and AST were significantly obvious in the
combined therapy groups (P < 0.01 or P < 0.05). In addition, the lower dosage of combined therapy significantly
ameliorated severe fatty degeneration of liver cells occurred in the high fat diet fed rat although the single
fenofibrate treatment showed spotty necrosis of liver cells and bile duct expansion.
Conclusion: Combination therapy with allicin and fenofibrate can effectively enhance the protective effects on
endothelial function and reduce the hepatic damage in rats with hyperlipidemia.
Background
Dyslipidemia and subsequent atherosclerosis are recog-
nized as the most dangerous inducers of ischemic cardi-
ovascular disease (ICD) at present. Numerous research
results demonstrated that the damage of vascular
endothelial function (DVEF) as the early detectable
alteration of ICD occurred before the appearance of
typical evidences of ICD [1]. Therefore, the prevention
and treatment of DVEF have a significant implication
for the hyperlipidemic patients. Several researches
indicated that fenofibrate as an important lipid-regulat-
ing drug could ameliorate vascular endothelial function
(VEF) as well [2,3]. However, a long-term and high-dose
application of fenofibrate could induce the possibility of
liver function damage (LFD) [4,5]. In order to regulate
blood lipid effectively, protect VEF and avoid the occur-
rence of drug-induced liver injury at the maximum
degree, we investigated the protective effect of combina-
tion of allicin and fenofibrate on VEF as well as the
combination influence on liver function in hyperlipi-
demic rats to provide definite theoretical and experi-
mental basis for the clinical medication. * Correspondence: shucunqin2001@yahoo.com
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Animal and Feed
SPF Wistar rat (220~250 g, 4 months old) were pro-
vided by the laboratory animal center of Shandong
Lukang Pharmaceutical Group (Animal Certification
No.: SCXK LU 20080002). Chow diet was the standard
feed offered by the laboratory animal center of Taishan
Medical University, and the high-fat diet was consisted
of cholesterol 2.0%, sodium cholate 0.5%, lard 10.0%,
propylthiouracil 0.2%, white sugar 5.0% and basal feed
82.3% (corn flour 36%, wheat flour 35%, wheat bran
15%, soybean flour 10%, yeast powder 1%, salt 1%, bone
powder 1% and fish liver oil 1%). The animal treatment
was strictly carried out according to the guide lines of
the laboratory animal ethical committee.
Drug and Reagent
Allicin soft capsules were obtained from Xinjiang Xinbei
Pharmaceutical Co., Ltd., and the lot number was
080911. Fenofibrate capsules used were from Labora-
toires Fournier S. A., and the lot number was
H20050004. Cholesterol and sodium cholate (analytical
pure) were purchased from Beijing Solarbio Science &
Technology Co., Ltd. and Shanghai Lanji Technology
Development Co., Ltd., respectively. Propylthiouracil
was the product of Shanghai Zhaohui Pharmaceutical
Co. Ltd., and the lot number was 081206. Sodium pen-
tobarbital was obtained from Sinopharm Chemical
Reagent Shanghai Co., Ltd. (Imported and load sepa-
rately). Phenylephrine (PHE) and acetylcholine chloride
(Ach) were purchased from Sigma. Assay kits for total
cholesterol (TC), triglyceride (TG), low-density lipopro-
tein cholesterol (LDL-C) and high-density lipoprotein
cholesterol (HDL-C) used were from Zhejiang Elikan
Biological Technology Co., Ltd. Assay kit for nitric
oxide (NO) was obtained from Nanjing Jiancheng Bioen-
gineering Institute. Assay kits for alanine transferase
(ALT) and aspartate transferase (AST) were provided by
Shanghai Kehua Dongling Diagnostic Products Co., Ltd.
All the other reagents used were of the analytical pure.
Major apparatus
Out body tissue organ constant temperature perfusion
system (Chengdu Technology & Market Co., Ltd.), TL-
18 M High speed tabletop refrigerated centrifuge
(Shanghai Centrifuge Institute Co., Ltd.), 7600-020
Automatic bio-chemical analysis instrument (Hitachi,
Ltd., Japan), 755B UV Visible spectrophotometer
(Shanghai Precision & Scientific Instrument Co., Ltd.),
820 Microtome (AO Co., America), ZP-1 Film launching
apparatus (Tianjin Tianli Aivation Electro-mechanical
Co., Ltd.), Microscope and BX51 Micro-camera system
(Olympus Corporation).
Animal Modeling and Grouping
Sixty male Wistar rats were randomly allocated into
normal control group, model group, fenofibrate group,
allicin group, and combination group, each group con-
sisted of 12 rats. The animals were acclimated for one
week prior to duplication of hyperlipemia model for
4 weeks, and then drug intervention for 8 weeks after the
model was established successfully. Normal control group
was fed with general diet, model control and fenofibrate
group were fed with high-fat diet, whilst allicin was
added to the high-fat diet for allicin group and combina-
tion group at a dose of 60 mg/kg·d and 20 mg/kg·d,
respectively. Fenofibrate group and combination group
were orally administrated with fenofibrate at a dose of 80
mg/kg and 30 mg/kg once a day, respectively. Normal
control group, model group and allicin group were admi-
nistrated with the same volume of distilled water orally
once a day. After consecutive drug intervention for 8
weeks, till the end of the 12 weeks’ experiment, one rat
died in normal control group, three rats died in model
group, and two rats died in each of the rest three groups.
Observation Indexes
Blood was sampled by tail-cutting method at the end of
the fourth week for blood lipids measurement to con-
firm successful establishment of the hyperlipemia model.
The rats were anaesthetized by injection of sodium pen-
tobarbital 50 mg/kg, and then were executed after
abdominal aorta blood sampling, and subsequently,
the blood lipid, serum NO, ALT and AST levels were
detected. Thoracic aortas from the rats were used to
prepare thoracic aorta rings for isolated relaxation effect
measurement, and the liver tissue samples were pre-
pared for histomorphological examination. (1) Measure-
ment of Blood Lipid: Serum TC and TG were
determined according to liquid double-reagent enzy-
matic method, and HDL-C and LDL-C were assessed by
direct method on a Hitachi 7600-020 automatic bio-che-
mical analysis instrument. (2) Measurement of serum
NO: Nitric acid reductase method. (3) Measurement of
Serum ALT and AST: Serum ALT and AST levels were
detected by UV-lactate dehydrogenase method and UV-
malate dehydrogenase method, respectively, on a Hitachi
7600-020 automatic bio-chemical analysis instrument.
(4) Function measurement of endothelium-dependent
vascular relaxation (EDVR) [6]: After abdominal aorta
blood sampling, the anaesthetized rats by injection of
sodium pentobarbital 50 mg/kg were subjected to thora-
cotomy rapidly, the isolated thoracic aortas were kept at
37 °C Krebs-Henseleit (K-H) solution with persistent
airing commixed gas composed of 95% Oxygen and 5%
carbon dioxide. The thoracic aorta from each rat was
made into thoracic aorta rings with a length of 3 mm by
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damage rings were carefully moved to a thermostatic
water bath containing 37 °C K-H solution with persis-
tent airing the above commixed gas, the downside of
the rings were immobilized to the bottom of the ther-
mostatic bath by steel-hooks, while their upside was
connected to BL-420 biological and functional experi-
mental system through tension transducers, the rest ten-
sion was adjusted to 1.5 g (tested to be the optimum
tension by pre-experiment) and balanced for 30 min-
utes. And then, potassium chloride solution (with a final
concentration of 50 mmol/L in the bath solution) was
added to give pre-stimulation for two times. After ten-
sion balance, PHE with a final concentration of 1 × 10
-6
mol/L was added to the thermostatic bath to make the
t h o r a c i ca o r t ar i n g sh a v eap r e - c o n t r a c t i o n ,a n do n c e
the contraction of the rings reached the platform stage,
a sequence increasing concentration of Ach (accumu-
lated concentration) with a final concentration of 1 ×
10
-8mol/L, 5 × 10
-8mol/L, 1 × 10
-7mol/L...... and 5 × 10
-
4mol/L, respectively, was used for inducing vasodilation,
and the induced tension alterations of the thoracic aorta
rings were recorded synchronously. Using relaxation
rate induced by PHE to express the relaxation effect
induced by Ach under different accumulated concentra-
tions, and thus, Relaxation Degree = (tension of the ring
induced by PHE - tension of the ring induced by Ach) ÷
tension of the ring induced by PHE × 100%. (5) Liver
histomorphological examination: The isolated fresh liver
tissues were immediately fixed with paraformaldehyde
for 24 h, and after ethanol dehydration and regular
paraffin embedding, they were made into 5 μm paraffin
slices, and finally applied to HE staining.
Statistical analysis
All the data were expressed as means ± standard devia-
tion (SD). The measurement data of multiple groups
were compared with one-way ANOVA, the comparison
between two groups was performed with (LSD) T-Test,
and a value of P < 0.05 was considered significant.
Results
Hyperlipemia Rat Model Induced by High-fat Diet
Four weeks feed resulted in significant increase of serum
TC, TG, LDL-C and HDL-C levels (P < 0.01) in high-
fat diet groups compared to normal control group
(Table 1). However, there was statistically non-signifi-
cant within groups of high-fat diet.
Influence of drug intervention on rat blood-lipid levels
As shown in Table 2, compared with the normal control
group, serum TC, TG, LDL-C and HDL-C levels were
increased dramatically (P < 0.01) in the other four
groups. Serum TC, TG, LDL-C and HDL-C levels of the
drug intervention groups decreased significantly (P <
0.01), while serum HDL-C levels of fenofibrate group
and combination group enhanced remarkably (P < 0.05)
compared to model control group. Serum LDL-C level
of the allicin group also reduced but the lowering degree
exceeded neither that of fenofibrate group (P < 0.01) nor
that of combination group (P < 0.01) with a lower
dosage. Furthermore, serum LDL-C level of combination
group was slightly lower than the group treated with
fenofibrate alone, but not reach statistical significant.
Influence of drug intervention on rat serum NO levels
Compared with the normal control group, serum NO
levels of the rest groups were reduced markedly (P <
0.01 or P < 0.05). However, serum NO level of the alli-
cin group increased and closed to that of fenofibrate
group when comparing with model control group,
additionally, combination group seemed to have the
most significant increase, but showed no additive effect
(Table 2).
Influence of drug intervention on rat ALT and AST levels
Compared with normal control group, serum ALT and
AST levels of the rest groups were all increased mark-
edly (P < 0.01 or P < 0.05). Serum ALT and AST levels
lowered significantly in the drug intervention groups
(P < 0.01) when comparing with model control group. In
addition, serum ALT and AST levels markedly reduced
in allicin group and combination group compared to
fenofibrate group (P < 0.01) (Table 3).
Function Alteration of Thoracic aorta EDVR and Influence
of Drug Intervention on Hyperlipemia Rat
Relaxation degrees of thoracic aorta rings of the model
control group were decreased remarkably (P < 0.01)
under each of the accumulated concentration of Ach
compared to the normal control group. However, com-
pared with the model control group, all of the relaxation
degrees of thoracic aorta rings of the drug intervention
groups significantly increased (P < 0.01) when the accu-
mulated concentration of Ach reached 5 × 10
-8 mol/L.
Furthermore, compared with single drug treatment
groups, allicin group and fenofibrate group, relaxation
degrees of thoracic aorta rings of combination group
raised dramatically (P < 0.05) since the accumulated
concentration of Ach reached 5 × 10
-5 mol/L, and
which seemed to have additive effect (Table 4).
Liver histomorphological examination: Naked-eye
observation
Livers of normal control group had regular shape with
sharp edges, and red with glossy. Livers of model
control group were hyperplastic with blunt edges, light
yellow, and cut surface was oily to the touch. The
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lied between the former two groups.
Optical microscope inspection
In normal control group, the hepatic lobules had clear
structure, hepatocytes arranged orderly with cell
nucleuses located centrally and without fatty denaturali-
zation. However, in model control group, hepatic cord
arranged in disorder, structure of hepatic lobules were
damaged, with many lipid-droplets vacuoles in hepato-
cytes, which showed serious fatty denaturalization. In
fenofibrate group, hepatocytes had mild fatty denaturali-
zation with spotty necrosis and expanded bile ductule.
The fatty denaturalization of hepatocytes decreased
obviously in garlic group and combination group, and
did not find spotty necrosis and expanded bile ductule
in the latter group, furthermore, the disordered hepato-
cytes were restored to some extent in combination
group (Figure 1).
Discussion
Vascular endothelium as a widely distributed and an
active metabolism organ (or system) with various bioac-
tivity plays an important role in maintaining the stability
of the vascular function, and the damage of VEF as the
early detectable alteration of atherosclerosis is closely
correlated with the occurrence and development of
atherosclerosis [7]. The secretion decrease of endothe-
lium derived relaxing factor (EDRF, that is NO) with
vasodilative effect, is the most obvious phenomenon
accompanied with the damage of VEF, therefore, serum
NO level and function of thoracic aorta EDVR were
measured to evaluate the VEF in this study.
This research showed that high-fat diet could induce
hyperlipidemia in rats, and hyperlipidemia could
decrease serum NO level and reduce function of EDVR
significantly. The exact occurrence mechanism of
damage of VEF induced by hyperlipidemia is not clearly
understood, however, the endothelium derived NO is
acknowledged to play a key role in regulating VEF.
Some results indicated that LDL particles not only could
enter the arterial walls easily but also be prone to oxida-
tive modification, and the oxidized LDL have high
cytotoxicity, which could directly damage vascular
endothelium. Through inhibiting activity of nitric oxide
synthase to reduce the production of NO or by inducing
the high expression of adhesion molecules at the surface
of the endothelial cells to promote inflammatory
response, and finally lead to the damage of VEF [8].
It has been reported that ‘high-fat diet’ can induce
lipid accumulation in rat liver by a nutritional interven-
tion [9]. Other studies have revealed that high-fat diets
promote hyperlipidemia [10] and hyperglycemia [11],
and numerous researchers have examined their effects
on muscle and liver physiology as well as endothelial
function [12-14]. From this experience, it is generally
accepted that high-fat diets can be used to generate a
valid rodent model for the analysis of the pathophysiol-
ogy of dyslipidemia [15-17]. Therefore, in this study,
high fat diet-induced dyslipidemia rat model was used
to examine the combined effects of allicin and fenofi-
brate on dietary induced lipoprotein changes and liver
damage.
As a synthetic ligand of peroxisome proliferator-
activated receptor a (PPARa), the main function of
fenofibrate, a phenoxy aromatic acid lipid-lowering
Table 1 Serum lipids in rats before administration of medication
Groups n TC(mmol/L) TG(mmol/L) HDL-C(mmol/L) LDL-C(mmol/L)
Normal control 11 1.760 ± 0.305 0.501 ± 0.086 1.362 ± 0.143 0.245 ± 0.034
Model control 9 4. 929 ± 2.142
a 0.922 ± 0.178
a 1.578 ± 0.173
a 2.428 ± 0.513
a
Fenofibrate 10 5.153 ± 2.668
a 0.908 ± 0.228
a 1.662 ± 0.141
a 2.370 ± 0.539
a
Allicin 10 4. 893 ± 2.105
a 0.948 ± 0.251
a 1.626 ± 0.129
a 2.499 ± 0.489
a
Combination 10 5.007 ± 2.377
a 0.949 ± 0.241
a 1.590 ± 0.149
a 2.421 ± 0.460
a
TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Values are means ± SD; a: Compared
to Normal control, P < 0.01
Table 2 Serum lipids and NO levels in rats at the end of 12 weeks treatment
Groups n TC(mmol/L) TG(mmol/L) HDL-C(mmol/L) LDL-C(mmol/L) NO(μmol/L)
Normal control 11 1.726 ± 0.199 0.519 ± 0.053 1.344 ± 0.109 0.252 ± 0.024 38.047 ± 3.604
Model control 9 10.592 ± 2.258
a 1.789 ± 0.078
a 1.722 ± 0.092
a 6.272 ± 0.552
a 23.649 ± 4.875
a
Fenofibrate 10 4.853 ± 0.670
ac 0.668 ± 0.061
ac 1.832 ± 0.065
ad 2.370 ± 0.263
ac 32.729 ± 2.906
bc
Allicin 10 5.183 ± 0.718
ac 0.738 ± 0.071
ac 1.793 ± 0.051
a 3.049 ± 0.278
ace 30.520 ± 3.194
ac
Combination 10 4.307 ± 0.490
ac 0.689 ± 0.060
ac 1.829 ± 0.055
ad 2.251 ± 0.367
ac 33.019 ± 3.879
bc
TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; NO: nitric oxide; Values are means ±
SD; a and b: Compared to Normal control, a P < 0.01, bP < 0.05; c and d: Compared to Model control, cP < 0.01, dP < 0.05; e: Compared to Fenofibrate,
e P < 0.01
Li et al. Lipids in Health and Disease 2010, 9:131
http://www.lipidworld.com/content/9/1/131
Page 4 of 7drug, is to reduce serum TG, but it also could decrease
serum TC and LDL-C, increase HDL-C, and decrease
the contents of LDL-C particles and apolipoprotein B
(ApoB) to some extent [18]. Our present findings indi-
cated that fenofibrate could ameliorate the abnormal
blood lipid alteration in rats with hyperlipidemia as well
as improve function of thoracic aorta EDVR, all of
which were consistent with earlier studies that have
demonstrated that fenofibrate could ameliorate blood
stream mediated vasodilation in brachial artery in
patients with hyperlipidemia [2,3]. The protective
mechanism of fenofibrate on VEF may be related with
other underlying factors except for its lipid regulating
effect. Some results revealed that fenofibrate could
increase the synthesis of NO through upregulating gene
expression of endothelial NO synthase (eNOS) directly
or by activating PPARa to inhibit signaling pathways
associated with inflammatory response, and subse-
quently increase the activity of eNOS [19].
As a food material which can be used as medicine and
food, garlic has been widely used as edible food for
thousands of years in Asian countries such as China.
Allicin, with the chemical name of diallyl thiosulfinate,
and the major pharmacological component of garlic, has
attracted attention of the international medical field gra-
dually due to its therapeutic effects on various cardio-
vascular diseases. Results indicated that garlic extract
could decrease serum TC and LDL-C levels markedly
and increase HDL-C level in animals [20,21], and
improve the serum TC and LDL-C levels significantly in
clinical research [22]. Williams MJ et al. [23] have
showed that garlic extract could ameliorate the damaged
VEF in patients with coronary heart disease. Gonen A et
al. [24] studied the anti-atherosclerosism e c h a n i s mo f
p u r ea l l i c i ni nA p o E
-/-/LDLR
-/- double-gene mutant
mice, and results indicated that allicin could exert anti-
atherosclerosis effects through lipoprotein modification
or by inhibiting phagocytic uptake and degradation of
LDL, except for antioxidant. This study showed that alli-
cin could effectively decrease serum TC, TG and LDL-C
levels in hyperlipidemia rats, while the HDL-C level did
not change significantly, moreover, VEF gained protec-
tion, all of which were basically consisted with the pre-
vious reports. This report demonstrated for the first
time that halving dosage combination of garlic and feno-
fibrate have an equivalent effect on lipid regulating
effect in hyperlipidemia rats with that of double dosage
of fenofibrate alone, and the former could improve pro-
tective effect on VEF compared with single usage of
either garlic or fenofibrate. The research indicated that
garlic and fenofibrate have synergistic effects on regulat-
ing blood lipid and improving VEF, additionally, the
combination exist other underlying mechanism on ame-
liorating VEF except for that of lipid regulation.
Another important discovery of the research is that com-
bination of garlic and fenofibrate could reduce damage of
liver function as well as drug-induced liver injury. Fibrates
(including fenofibrate) like most of the other presently
applied clinical lipid regulating drugs have some serious
toxic and side effects, such as the uprising of serum transa-
minase and creatine kinase, therefore, they are unsuitable
for the patients with serious diseases associated with liver,
gall bladder and kidney. Research in recent years indicated
that application of fenofibrate at the dose of 300 mg/kg·d
for 14 days, the liver function got serious damage except
for the increase of b-oxidation of fatty acid and decrease
Table 3 Serum ALT and AST levels in rats at the end
of 12 week treatment
Groups n ALT(U/L) AST(U/L)
Normal control 11 35.364 ± 2.730 81.546 ± 5.087
Model control 9 70.333 ± 3.500
a 134.778 ± 4.790
a
Fenofibrate 10 49.200 ± 4.022
ac 102.100 ± 5.840
ac
Allicin 10 41.500 ± 3.375
acd 92.100 ± 5.763
acd
Combination 10 42.100 ± 3.665
acd 90.400 ± 8.343
bcd
ALT: alanine transferase; AST: aspartate transferase; Values are means ± SD; a
and b: Compared to Normal control,
aP<0 . 0 1 ,
bP < 0.05; c: Compared to
Model control, P < 0.01; d: Compared to Fenofibrate, P < 0.01
Table 4 Ach-induced vascular relaxation of aorta rings in rats at the end of 12 week treatment (%)
Ach (mol/L) Normal control Model control Fenofibrate Allicin Combination
1×1 0
-8 9.504 ± 3.361 4.894 ± 1.838
a 7.924 ± 3.095 7.727 ± 2.524 8.160 ± 2.661
5×1 0
-8 29.501 ± 5.825 10.468 ± 4.811
a 19.967 ± 5.227
ac 21.199 ± 5.952
bc 24.344 ± 6.081
c
1×1 0
-7 45.167 ± 6.798 21.421 ± 4.423
a 35.535 ± 5.401
ac 37.791 ± 6.251
bc 38.110 ± 4.599
bc
5×1 0
-7 59.172 ± 5.920 28.409 ± 5.214
a 42.072 ± 6.291
ac 43.341 ± 3.877
ac 45.893 ± 5.357
ac
1×1 0
-6 65.610 ± 4.660 33.799 ± 5.341
a 51.420 ± 5.638
ac 50.197 ± 6.689
ac 53.360 ± 5.938
ac
5×1 0
-6 78.351 ± 5.409 41.251 ± 4.535
a 59.392 ± 5.384
ac 57.945 ± 3.376
ac 61.576 ± 3.600
ac
1×1 0
-5 84.039 ± 3.895 45.537 ± 4.862
a 66.847 ± 5.710
ac 64.017 ± 4.827
ac 69.594 ± 4.474
ac
5×1 0
-5 86.903 ± 4.872 49.129 ± 5.366
a 68.593 ± 4.449
ac 67.532 ± 3.549
ac 75.037 ± 5.364
acd
1×1 0
-4 89.075 ± 4.248 48.627 ± 4.031
a 67.903 ± 4.853
ac 67.182 ± 5.459
ac 74.959 ± 4.344
acd
Ach: Acetylcholine; Values are means ± SD; a and b: Compared to Normal control,
aP < 0.01,
bP < 0.05; c: Compared to Model control, P < 0.01; d: Compared to
Fenofibrate, P < 0.05
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stress participated this process [4]. Some experiments in
vitro indicated that high concentration fenofibrate could
mediate death of human hepatoblastoma cells (HepG2)
through enhancing reactive oxygen species or by inhibiting
synthesis of glutathione, which confirmed that oxidative
stress did participated in the cytotoxicity of fenofibrate [5].
Compared with single usage of fenofibrate with double
dosage, halving dosage combination of garlic and fenofi-
brate could significantly alleviate damage of liver function,
which may related with the dosage difference of fenofi-
brate on the one hand. In addition, garlic may antagonize
the hepatotoxicity of fenofibrate to some extent when con-
sidering its antioxidant activity, however, the exact
mechanism requires additional research.
Conclusions
This study indicated that halving dosage combination of
garlic and fenofibrate have an equivalent effect on lipid
regulating effect in hyperlipidemia rats with that of
double dosage of fenofibrate alone. Combination could
improve protective effect on VEF, and reduce damage of
liver function induced by hyperlipidemia as well as drug-
induced liver injury, however, the underlying mechanism
of combination on ameliorating VEF except for that of
lipid regulation and the exact mechanism of alleviating
drug-induced liver injury need to be further investigated.
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